Eli Lilly (LLY) valuation review: obesity drugs fuel growth, but upside looks limited with ~8.5% IRR. Read here for a detailed investment analysis.

Eli Lilly (NYSE:LLY) is in focus as pharma-administration pricing deals ease sector pressure and its obesity drug franchise and oral pill program stay in the spotlight.

Gate deal potential reaches USD 870.00 million. Eli Lilly stock costs EUR 1,046.20 on October 7, 202

Peptron has concluded a two-year technology evaluation of its SmartDepot platform with Eli Lilly. With no announcement of a follow-on…

Eli Lilly stock was at EUR 1031.30 pre-market at 8:16 a.m. CEST on October 7, 2026, up plus 0.16 per

Top and bottom line beats, with broad drug sales momentum, along with beefy gross margins, made Eli Lilly to raise FY 2026 guidance. Read why LLY stock is a Buy.

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a +1.26% move from the prior day.

Eli Lilly (NYSE:LLY) wins expanded Jaypirca approval and reports Foundayo safety data as healthcare stays in focus.

Eli Lilly stock traded at USD 1,161.69 on October 6, 2026, up 1.62 percent as Foundayo data sharpen

Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.

Shionogi is acquiring IntraBio for $2 billion, Gate Bioscience expands its collaboration with Eli Lilly, and Alector licenses Al050 to Genentech.

Eli Lilly outlook: Foundayo driving oral GLP-1 share and FY2026 upside. Click for more on LLY stock.

At the European Association for the Study of Diabetes meeting in Milan, Eli Lilly and Company (NYSE:LLY) presented data showing that its oral GLP-1 pill, Foundayo, delivered greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes. The bigger question is what this means for a […]

Eli Lilly stock follows a USD 870 million collaboration expansion announced on October 5, 2026. Q2 r